Lyra Misses Endpoint in Phase 3 in Chronic Rhinosinusitis

 The ENLIGHTEN 1 trial is ongoing and data from the 52-week extension phase are expected in Q4 2024. ENLIGHTEN 2, the second pivotal Phase 3 trial of LYR-210 in CRS, is ongoing.

The Company expects to make near-term changes to its business operations and to reduce its workforce in order to preserve cash.

https://www.globenewswire.com/news-release/2024/05/06/2875729/0/en/Lyra-Therapeutics-Reports-Topline-Results-from-Phase-3-ENLIGHTEN-1-Trial-for-LYR-210-in-Chronic-Rhinosinusitis.html